Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-53279

Pirker, R; Herth, F J F; Kerr, K M; Filipits, M; Taron, M; Gandara, D; Hirsch, F R; Grunenwald, D; Popper, H; Smit, E; Dietel, M; Marchetti, A; Manegold, C; Schirmacher, P; Thomas, M; Rosell, R; Cappuzzo, F; Stahel, R (2010). Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. Journal of Thoracic Oncology, 5(10):1706-1713.

[img]Published Version
PDF - Registered users only
517kB

View at publisher

Abstract

INTRODUCTION:

Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC). Patients harboring these mutations in their tumors show excellent response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The EGFR-TKI gefitinib has been approved in Europe for the treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of the EGFR TK. Because EGFR mutation testing is not yet well established across Europe, biomarker-directed therapy only slowly emerges for the subset of NSCLC patients most likely to benefit: those with EGFR mutations.
METHODS:

The "EGFR testing in NSCLC: from biology to clinical practice" International Association for the Study of Lung Cancer-European Thoracic Oncology Platform multidisciplinary workshop aimed at facilitating the implementation of EGFR mutation testing. Recommendations for high-quality EGFR mutation testing were formulated based on the opinion of the workshop expert group.
RESULTS:

Co-operation and communication flow between the various disciplines was considered to be of most importance. Participants agreed that the decision to request EGFR mutation testing should be made by the treating physician, and results should be available within 7 working days. There was agreement on the importance of appropriate sampling techniques and the necessity for the standardization of tumor specimen handling including fixation. Although there was no consensus on which laboratory test should be preferred for clinical decision making, all stressed the importance of standardization and validation of these tests.
CONCLUSION:

The recommendations of the workshop will help implement EGFR mutation testing in Europe and, thereby, optimize the use of EGFR-TKIs in clinical practice.

Citations

Altmetrics

Downloads

2 downloads since deposited on 12 Jan 2012
0 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
DDC:610 Medicine & health
Language:English
Date:2010
Deposited On:12 Jan 2012 22:14
Last Modified:25 Dec 2012 22:30
Publisher:Lippincott Wiliams & Wilkins
ISSN:1556-0864
Publisher DOI:10.1097/JTO.0b013e3181f1c8de
PubMed ID:20871269

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page